OncoMatch/Clinical Trials/NCT07174908
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Is NCT07174908 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including IN10018 in combination with D-1553 and anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed for non-small cell lung cancer.
Treatment: IN10018 in combination with D-1553 · anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed — This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the locally advanced or metastatic KRASG12C mutation-positive non-squamous non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: KRAS g12c
Required: ROS1 wild-type
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: KRAS inhibitor
Prior treatment with KRAS G12C inhibitors
Cannot have received: FAK inhibitor
Prior treatment with FAK inhibitors
Cannot have received: checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors
Lab requirements
Blood counts
Kidney function
Liver function
Has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07174908 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages